Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
RLD2301 + RLD2007
- Development stage
- Phase 1
- Lead developer
- Hanmi Pharmaceutical
- Administration
- Oral
01
Overview
RLD2301 + RLD2007 is a combination of two investigational pharmaceutical agents developed by Hanmi Pharmaceutical, evaluated primarily for their drug-drug interaction and safety profile following oral administration in healthy adult volunteers. Both agents have been tested in a crossover design to assess pharmacokinetics, safety, and tolerability. Specific information regarding their molecular structure, precise pharmacological class, or mechanisms of action is not disclosed in the public domain.
Beyond the preview
Go deeper on RLD2301 + RLD2007.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RLD2301 + RLD2007.